Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Ultimately improve the care of patients suffering from multiple sclerosis (1st cause of acquired non-traumatic disability in adults) and NMO spectrum diseases by using more efficient MRI sequences than the FLAIR sequence commonly used in detection of optic neuritis. In the literature, many studies have already focused on comparing the sensitivity of detection of white matter demyelination plaques using FLAIR, PSIR or DIR sequences. Some authors have shown better sensitivity of the PSIR sequence in the detection of demyelinating lesions of the marrow in multiple sclerosis compared to conventional sequences. Others have shown better performance of the combined use of PSIR and DIR sequences compared to the FLAIR sequence in the detection of cortical lesions in multiple sclerosis. However, in the context of optic neuritis, few comparative studies comparing these three sequences have been carried out: A 2022 study showed better diagnostic sensitivity of optic neuritis of the DIR sequence compared to the FLAIR sequence. A possible better diagnostic performance of a sequence not used in current practice in the detection of optic neuritis (PSIR and DIR sequences), would be possible to justify their use on a larger scale and ultimately improve patient care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Major subject (≥18 years old)

• Subject suffering from multiple sclerosis or an NMO spectrum disease

• Subject having received an MRI including 3D FLAIR, 3D DIR and 3D PSIR sequences

• Brain MRIs of eligible subjects acquired between April 1, 2019 and November 30, 2021.

• No opposition to the reuse of its data for scientific research purposes.

Locations
Other Locations
France
Service de Radiologie II, CHU de Strasbourg
RECRUITING
Strasbourg
Contact Information
Primary
François-Daniel ARDELLIER, MD
francois-daniel.ardellier@chru-strasbourg.fr
33 3 68 76 53 37
Time Frame
Start Date: 2024-01-19
Estimated Completion Date: 2025-01-19
Participants
Target number of participants: 60
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov